PUBLISHER: Grand View Research | PRODUCT CODE: 1888676
PUBLISHER: Grand View Research | PRODUCT CODE: 1888676
The global pharma hub and patient access support service market size was estimated at USD 3.24 billion in 2024 and is projected to reach USD 7.63 billion by 2033, growing at a CAGR of 10.0% from 2025 to 2033. The growth is attributed to the increasing need to administer new medicines for various specialties and rare & orphan diseases, prioritizing creating a patient-centric ecosystem.
Payer-side complexity (prior authorizations, specialty drug formularies, and rising claim denials), and tighter affordability controls have pushed manufacturers to outsource patient onboarding, benefiting verification and copay/cost-assistance management to dedicated hub providers.
The growing launch of high-cost specialty and rare-disease therapies between 2021 and 2024 has become a key driver for the expansion of pharma hubs and patient access support services. According to the U.S. FDA, 37 novel drugs were approved in 2022, of which 20 around 54% were targeted at rare diseases, while in 2023, 55 new drugs were approved, and over half, 28 drugs, were for rare diseases. These therapies often carry exceptionally high price tags and require complex insurance approvals.
Hemgenix, a gene therapy for hemophilia B approved in 2022, was priced at about USD 3.5 million per dose, and Alzheimer's drug Leqembi, approved in 2023, costs around USD 26,500 annually. Such launches highlight the growing financial and administrative barriers for patients, encouraging pharmaceutical companies to invest heavily in digital hub platforms, benefit verification systems, prior authorization automation, and patient support programs. As a result, the increasing number of specialized, high-cost therapies is directly driving demand for integrated pharma hub and patient access support solutions to streamline reimbursement, accelerate therapy initiation, and improve adherence outcomes.
The market is further driven by players undertaking several strategic initiatives. For instance, in November 2023, Docquity announced the expansion of its digitized patient access program, DocquityCare PAP, to Thailand. It launched five PAPs in Thailand, supporting 250 authorized HCPs and around 100 enrolled hospitals to enhance patient care for individuals with cancer and additional life-threatening conditions.
Global Pharma Hub And Patient Access Support Service Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pharma HUB and patient access support service market report based on service type, service delivery type, and region: